Our promise to you:
Guaranteed product quality, expert customer support.
Antagomir is chemically-modified single-strand miRNA inhibitor functioning by blocking miRNA regulation of target gene expression efficiently. They are synthesized to reduce the ability of endogenous miRNAs to silence target mRNA transcripts. They can down-regulate the corresponding endogenous miRNAs by either local or systemic injection into the animals.
Creative Biogene's microDOWN™ miRNA antagomir is single-strand miRNA inhibitor carrying the chemically modifications functioning by blocking miRNA regulation of target gene expression efficiently. The strand of the antagomir has 2 phosphorothioates at the 5' end, 4 phosphorothioates, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. Stability of microDOWN™ miRNA antagomir appears to be significantly higher than miRNA inhibitors. It exhibits enhanced cellular uptake, stability and regulatory activity and is recommended for miRNA functional studies in vitro and in vivo.
Figure 1. Mechanism of microDOWN™ miRNA antagomir.
Figure 2. qRT-PCR and western blot assays show the mRNA (A) and protein (B) expressions of TOB1 after transfection with antagomir-NC and antagomir-25.
Our microDOWN™ miRNA antagomir has unparalleled advantages
Recommended amounts of microDOWN™ antagomir for your cell assay.
|Shan Y, et al. Gastroenterology. 2007||miR-122||Huh-7 WT, CNS3||50 nM|
|Brian D, et al. Mol Ther. 2007||miR-206||HeLa, MDA-231, MCF-7||20-50 nM|
|Zhu H, et al. Biochem Pharmacol. 2008||miR-27a, miR-451||A2780||100 nM|
|Alla Musiyenko, et al. J Mol Med. 2008||miR-126, miR-126||LNCaP||10~30 nM|
|Jia Yu, et al. PNAS. 2008||miR-184, miR-205||HeLa, HEKs||1 μM|
|Federica et al. Cancer Res. 2008||miR-221, miR-222||Me665/1||50~250 nM|
|Relja Popovic, et al. Blood. 2009||miR-196b||bone marrow cells||100 nM|
|Pascal Pineau, et al. PNAS. 2010||miR-221, miR-222||hepatocellular carcinoma-derived||100 μM|
|Xiaogang Wang, et al. Nat Med. 2012||miR-214||MC3T3-E1, hFOB||200 μM|
|Wang X, et al. Nat Med. 2013||miR-214||MC3T3-E1||200 nM|
In Vivo Delivery
|Krützfeldt J, et al. Nature. 2005||miR-122|
|6-week-old mice||tail-vein injections||80 mg per kg body weight||0.2 ml per injection||1 to 3 consecutive days||24 h after the last injection|
|Jan Krützfeldt, et al. Nucleic Acids Research. 2007||miR-16||6-week-old mice||Intracerebral injection||~800 ng per mouse||0.2 ml per injection||a single injection||72 h after injection|
|Alessandra Care, et al. Nature Medicine. 2007||miR-133||8-week-old mice||minipump implantation||80 mg per kg body weight||N/A||a single infusion||1 month after minipump implantation|
|Laura Fontana, et al. PLoS ONE. 2008||miR-17-5p||6-week-old nude mice||intratumorally injection||0.2 mg per mouse||0.1 ml||three times per week for two weeks||2 weeks after the first injection|
|Thomas Thum, et al. Nature. 2008||miR- 21||10~12 weeks old mice||jugular vein catheter||80 mg per kg body weight||N/A||injected daily for three days||3 weeks after the first injection|
|Neri Mercatelli, et al. PLoS ONE. 2008||miR-221 |
|6-week-old mice||intratumorally injection||1 ug of each antagomir||40 μl||at day 0, 5 and 9, for a injections per tumor||N/A|
|Ashuthosh Dharap, et al. J. Cereb. Blood Flow Metab. 2009||miR-145||rat||minipump implantation||totally 960 pmol each rat||48 μl||N/A||N/A|
|Li H, Xie H, et al. J Clin Invest. 2009||miR-2861||6-week-old female mice||tail vein injection||80 mg/kg body weight||0.2 ml per injection||days 1 to 3 for 3 consecutive weeks||4 days, 3 weeks, and 6 weeks after the last injection|
|Bonauer A, et al. Science. 2009||miR-92||mice||intravenous injection||8 mg per kg of body weight||0.2 ml per injection||at days 0, 2, 4, 7, 9 of the left coronary artery||14 days|
|Jie Ding, et al. Nature cell biology. 2010||miR-151-5p||nude mice||transplantion||2x106 cells transfected by antagomir||N/A||5 weeks after injection|
|LinHui Liang, et al. Hepatology. 2010||miR-125b||6~8 weeks old nude mice||subcutaneously injection||2x105 cells transfected by antagomir||N/A||4 weeks after injection|
|Minfeng Shu, et al. Molecular Cancer. 2011||miR-335||4-week-old nude mice||Intratumorally injection||4 mg/ml||50 μl||every two days for 2 weeks||2 weeks after the first injection|